



A CLINICAL TRIAL FOR YOUR PATIENTS WITH LUPUS OR LUPUS NEPHRITIS

The EQUALISE Clinical Trial

The EQUALISE trial is currently enrolling patients with lupus and lupus nephritis at sites in the United States, with plans to open additional sites outside of the U.S. in 2020.

This Phase 1b study will evaluate a range of possible doses of itolizumab in lupus patients, and characterize the safety, pharmacokinetics, pharmacodynamics and clinical activity of itolizumab in patients with lupus nephritis. The study will also explore novel biomarkers that may be predictive of disease activity and identify patients who are likely to respond to itolizumab.

About Itolizumab

Itolizumab, in development by Equillium, is an investigational antibody therapeutic that targets the newly defined CD6-ALCAM pathway to modulate both the activity and trafficking of T effector cells.

Eligibility

We're actively recruiting patients with:

1. Systemic lupus erythematosus (SLE) without lupus nephritis.
2. Active proliferative lupus nephritis.



Learn More

Please contact clinicaltrials@equilliumbio.com for more information, if you are interested in participating in the trial, or if you have a patient who may be eligible for the study.

For more details about the EQUALISE trial, including study design and inclusion criteria, please visit clinicaltrials.gov and search NCT04128579.

Itolizumab is an investigational medication and has not been approved to treat patients with systemic lupus erythematosus or lupus nephritis.

equillium®